EC-CvC

IARC hosted the final meeting of the first phase of the European Commission Initiative on Cervical Cancer and reported the outcome on 17 July 2026.

HPV DNA Testing

More than 20 experts reviewed evidence and advanced work on European guidelines and a quality assurance scheme for cervical cancer screening, diagnosis and care. The topics considered included HPV DNA and messenger RNA testing, self-sampling, appropriate ages for starting and stopping screening, screening intervals, risk-based triage and strategies for inviting eligible people. These questions are central to effective population programmes because the benefits of HPV-based screening depend on validated tests, clear follow-up pathways and systems that reach individuals who may not attend conventional services. Self-sampling may improve participation, but it also requires reliable laboratory procedures, communication and referral arrangements. The initiative combines clinical recommendations with a quality assurance framework so that countries can monitor whether services are being delivered consistently and safely.

First Phase

The first phase established the scientific and methodological foundation, while subsequent work is expected to complete and expand the guidance and quality requirements. This supports Europe’s broader objective of reducing cervical cancer incidence and inequalities through vaccination, organised screening and timely treatment of precancerous lesions. IARC’s involvement brings international expertise in cancer prevention and evidence evaluation, while the European Commission framework supports implementation across Member States. The meeting therefore represents a concrete step toward more harmonised, accessible and quality-assured cervical cancer prevention in Europe.

Direct link:
https://www.iarc.who.int/news-events/iarc-hosts-final-meeting-of-first-phase-of-ec-cvc/